The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 401–500 of 1,011
Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge
Clarke, S. F., Murphy, E. F., O’Sullivan, Ó., Ross, R. P., O’Toole, P. W., Shanahan, F., & Cotter, P. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065790 · Cited by 169
Nonalcoholic Fatty Liver Disease in Children
Mann, J. P., Valenti, L. V. C., Scorletti, E., Byrne, C. D., & Nobili, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1627456 · Cited by 169
Xia, H. H. X., & Talley, N. J. (1997) · PubMed · Cited by 161
Chiu, C.-C., Ching, Y.-H., Li, Y.-P., Liu, J.-Y., Huang, Y.-T., Huang, Y.-W., Yang, S.-S., Huang, W.-C., & Chuang, H.-L. (2017) · Nutrients · doi:10.3390/nu9111220 · Cited by 160
Leamy, L. J., Kelly, S. A., Nietfeldt, J. W., Legge, R. M., Ma, F., Hua, K., Sinha, R., Peterson, D. A., Walter, J., Benson, A. K., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0552-6 · Cited by 163
Dysbiosis in gastrointestinal disorders
Chang, C., & Lin, H. C. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.02.001 · Cited by 163
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
The Therapeutic Potential of Modifying Inflammasomes and NOD-Like Receptors
Virgilio, F. D. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006171 · Cited by 168
The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yu, Y., Raka, F., & Adeli, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122227 · Cited by 166
Moreno‐Fernandez, M. E., Giles, D. A., Oates, J. R., Chan, C. C., Damen, M. S. M. A., Doll, J., Stankiewicz, T. E., Chen, X., Chetal, K., Karns, R. A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.018 · Cited by 163
RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3
Lukens, J. R., Vogel, P., Johnson, G. R., Kelliher, M. A., Iwakura, Y., Lamkanfi, M., & Kanneganti, T. (2013) · Nature · doi:10.1038/nature12174 · Cited by 160
Montassier, E., Batard, É., Massart, S., Gastinne, T., Carton, T., Caillon, J., Fresne, S. L., Caroff, N., Hardouin, J.-B., Moreau, P., et al. (2014) · Microbial Ecology · doi:10.1007/s00248-013-0355-4 · Cited by 163
Non-alcoholic Fatty Liver Disease: A Clinical Update
Pappachan, J. M., Babu, S. V., Krishnan, B., & Ravindran, N. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00013 · Cited by 166
Zhang, X., Han, J., Man, K., Li, X., Du, J., Chu, E. S., Go, M. Y. Y., Sung, J. J. �., & Yu, J. Q. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.005 · Cited by 156
Molecular Control of Steady-State Dendritic Cell Maturation and Immune Homeostasis
Hammer, G. E., & Ma, A. I. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074929 · Cited by 158
Vijay-Kumar, M., Chassaing, B., Kumar, M., Baker, M. T., & Singh, V. K. (2014) · Biomedical Journal · doi:10.4103/2319-4170.130922 · Cited by 166
Gut microbiome and metabolic diseases
Fukuda, S., & Ohno, H. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0399-z · Cited by 156
Pyroptosis in Liver Disease: New Insights into Disease Mechanisms
Wu, J., Lin, S., Wan, B., Velani, B., & Zhu, Y. (2019) · Aging and Disease · doi:10.14336/ad.2019.0116 · Cited by 157
Abulikemu, A., Zhao, X., Xu, H., Li, Y., Ma, R., Yao, Q., Wang, J., Sun, Z., Li, Y., & Guo, C. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102569 · Cited by 155
Olesen, S. W., & Alm, E. J. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.228 · Cited by 154
He, W., Rahimnejad, S., Wang, L., Song, K., Lu, K., & Zhang, C. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.09.007 · Cited by 156
Ma, N., Zhang, J., Reiter, R. J., & Ma, X. (2019) · Medicinal Research Reviews · doi:10.1002/med.21628 · Cited by 155
Role of gut microbiota in liver disease
Albhaisi, S. A. M., Bajaj, J. S., & Sanyal, A. J. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00118.2019 · Cited by 155
Immune System: An Emerging Player in Mediating Effects of Endocrine Disruptors on Metabolic Health
Bansal, A., Henao-Mejia, J., & Simmons, R. A. (2018) · Endocrinology · doi:10.1210/en.2017-00882 · Cited by 152
Self-citationThe effect of past antibiotic exposure on diabetes risk
Boursi, B., Mamtani, R., Haynes, K., & Yang, Y. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1163 · Cited by 161
Bauer, C. A., Duewell, P., Lehr, H., Endres, S., & Schnurr, M. M. (2012) · Digestive Diseases · doi:10.1159/000341681 · Cited by 152
Alhasson, F. A., Das, S., Seth, R. K., Dattaroy, D., Chandrashekaran, V., Ryan, C. N., Chan, L. S., Testerman, T. L., Burch, J. B., Hofseth, L. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172914 · Cited by 152
Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis
Iacob, S. A., & Iacob, D. G. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01676 · Cited by 158
Mátyás, C., Haskó, G., Liaudet, L., Trojnár, E., & Pacher, P. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0433-5 · Cited by 152
Chen, R., Huang, S., Lin, T., Ma, H., Shan, W., Duan, F., Lv, J., Zhang, J., Ren, L., & Nie, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00844-6 · Cited by 154
Liu, C.-F., & Chien, L.-W. (2023) · Nutrients · doi:10.3390/nu15081892 · Cited by 152
Abais, J. M., Xia, M., Li, G., Chen, Y., Conley, S. M., Gehr, T. W. B., Boini, K. M., & Li, P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567537 · Cited by 153
Reproductive tract inflammatory disease in postpartum dairy cows
LeBlanc, S. J. (2014) · animal · doi:10.1017/s1751731114000524 · Cited by 151
The Gordian Knot of dysbiosis, obesity and NAFLD
Mehal, W. Z. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.146 · Cited by 156
Self-citationHigh Fat Diet Causes Depletion of Intestinal Eosinophils Associated with Intestinal Permeability
Johnson, A. M. F., Costanzo, A. E., Gareau, M. G., Armando, A. M., Quehenberger, O., Jameson, J., & Olefsky, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122195 · Cited by 164
Petrescu, M. D., Vlaicu, S. I., Ciumărnean, L., Milaciu, M. V., Mărginean, C., Florea, M., Vesa, Ș. C., & Popa, M. (2022) · Medicina · doi:10.3390/medicina58050641 · Cited by 150
Disease tolerance: concept and mechanisms
McCarville, J. L., & Ayres, J. S. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.12.003 · Cited by 154
Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome?
Anhê, F. F., Pilon, G., Roy, D., Desjardins, Y., Levy, E. H., & Marette, A. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1142036 · Cited by 155
Microbiota, Inflammation and Obesity
Sanz, Y., & Moya-Pérez, Á. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_14 · Cited by 151
Risk factors and outcome of bacterial infections in cirrhosis
Bruns, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2542 · Cited by 148
Gut microbiota and host metabolism in liver cirrhosis
Usami, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11597 · Cited by 152
Zhao, G., Zhang, P., Gong, J., Zhang, X., Wang, P., Yin, M., Jiang, Z., Shen, L., Ji, Y., Tong, J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4334 · Cited by 148
Acute liver failure is regulated by MYC- and microbiome-dependent programs
Kolodziejczyk, A. A., Federici, S., Zmora, N., Mohapatra, G., Dori-Bachash, M., Hornstein, S., Leshem, A., Reuveni, D., Zigmond, E., Tobar, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1102-2 · Cited by 149
Self-citationThe Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
Song, Q., & Zhang, X. (2022) · Biomedicines · doi:10.3390/biomedicines10030524 · Cited by 154
Loman, B. R., Hernández‐Saavedra, D., An, R., & Rector, R. S. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy031 · Cited by 147
Meroni, M., Longo, M., & Dongiovanni, P. (2019) · Nutrients · doi:10.3390/nu11112642 · Cited by 152
Developmental origins of nonalcoholic fatty liver disease
Brumbaugh, D. E., & Friedman, J. E. (2013) · Pediatric Research · doi:10.1038/pr.2013.193 · Cited by 152
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome
Wainwright, P., & Byrne, C. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030367 · Cited by 145
Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
Poeta, M., Pierri, L., & Vajro, P. (2017) · Children · doi:10.3390/children4080066 · Cited by 147
Unravelling the involvement of gut microbiota in type 2 diabetes mellitus
Arora, A., Behl, T., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Sobarzo‐Sánchez, E., & BUNGAU, S. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119311 · Cited by 147
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13688 · Cited by 148
Yahoo, N., Dudek, M., Knolle, P. A., & Heikenwälder, M. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 147
Verhelst, X., Dias, A. M., Colombel, J., Vermeire, S., Vlierberghe, H. V., Callewaert, N., & Pinho, S. S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.060 · Cited by 151
Carpi, R. Z., Barbalho, S. M., Sloan, K. P., Laurindo, L. F., Gonzaga, H. F., Grippa, P. C., Zutin, T. L. M., Gírio, R. J. S., Repetti, C. S. F., Detregiachi, C. R. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158805 · Cited by 147
Bahr, S. M., Weidemann, B. J., Castro, A. N., Walsh, J. W., deLeon, O., Burnett, C. M. L., Pearson, N. A., Murry, D. J., Grobe, J. L., & Kirby, J. R. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.018 · Cited by 143
Kim, S., & Lee, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.178 · Cited by 143
Gut microbiome and nonalcoholic fatty liver diseases
Zhu, L., Baker, R. D., & Baker, S. S. (2014) · Pediatric Research · doi:10.1038/pr.2014.157 · Cited by 147
The Genetics of Complex Cholestatic Disorders
Hirschfield, G. M., Chapman, R. W., Karlsen, T. H., Lammert, F., Lazaridis, K. N., & Mason, A. L. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.053 · Cited by 145
Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
Xu, G., Fu, S., Zhan, X., Wang, Z., Zhang, P., Shi, W., Qin, N., Chen, Y., Wang, C., Niu, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134601 · Cited by 143
Boaru, S. G., Borkham‐Kamphorst, E., Tihaa, L., Haas, U., & Weiskirchen, R. (2012) · Journal of Inflammation · doi:10.1186/1476-9255-9-49 · Cited by 142
Mohseni, A. H., Casolaro, V., Bermúdez‐Humarán, L. G., Keyvani, H., & Taghinezhad‐S, S. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1886844 · Cited by 143
Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology · doi:10.1002/hep.27297 · Cited by 141
Ceccarelli, S., Panera, N., Mina, M., Gnani, D., Stefanis, C. D., Crudele, A., Rychlicki, C., Petrini, S., Bruscalupi, G., Agostinelli, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5163 · Cited by 141
The digestive tract as the origin of systemic inflammation
de Jong, P. R., González-Navajas, J. M., & Jansen, N. J. G. (2016) · Critical Care · doi:10.1186/s13054-016-1458-3 · Cited by 146
Microbiota, NASH, HCC and the potential role of probiotics
Brandi, G., Lorenzo, S. D., Candela, M., Pantaleo, M. A., Bellentani, S., Tovoli, F., Saccoccio, G., & Biasco, G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx007 · Cited by 141
Delzenne, N. M., Knudsen, C., Beaumont, M., Rodriguez, J., Neyrinck, A. M., & Bindels, L. B. (2019) · Proceedings of The Nutrition Society · doi:10.1017/s0029665118002756 · Cited by 146
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Lymphotoxin regulates commensal responses to enable diet-induced obesity
Upadhyay, V., Poroyko, V. A., Kim, T.-J., Devkota, S., Fu, S., Liu, D., Tumanov, A. V., Koroleva, E. P., Deng, L., Nagler‐Anderson, C., et al. (2012) · Nature Immunology · doi:10.1038/ni.2403 · Cited by 145
The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension
Seo, Y. S., & Shah, V. H. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.4.337 · Cited by 141
The gasdermin family: emerging therapeutic targets in diseases
Zhu, C., Xu, S., Jiang, R., Yu, Y., Bian, J., & Zou, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01801-8 · Cited by 149
The role of the adaptive immune system in regulation of gut microbiota
Kato, L. M., Kawamoto, S., Maruya, M., & Fagarasan, S. (2014) · Immunological Reviews · doi:10.1111/imr.12185 · Cited by 141
Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Sasaki, H., Hirai, K., Martins, C. M., Furusho, H., Battaglino, R. A., & Hashimoto, K. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160216145107 · Cited by 140
miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123966 · Cited by 139
Schirbel, A., Kessler, S. P., Rieder, F., West, G. A., Rebert, N. A., Asosingh, K., McDonald, C., & Fiocchi, C. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.11.005 · Cited by 142
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136
Liang, Y., Shu, L., Zhang, Y., Deng, Y., He, Y., Chen, Y., Liu, C., Lin, C., & Yang, Q. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-017-9378-3 · Cited by 136
Immunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M. D. C., Lafdil, F., Kisseleva, T., Szabó, G., & Gao, B. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 140
Genetic determinants of gut microbiota composition and bile acid profiles in mice
Kemis, J. H., Linke, V., Barrett, K. L., Boehm, F. J., Traeger, L. L., Keller, M. P., Rabaglia, M. E., Schueler, K. L., Stapleton, D. S., Gatti, D. M., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008073 · Cited by 136
Manipulating the Gut Microbiota: Methods and Challenges: Figure 1
Ericsson, A. C., & Franklin, C. L. (2015) · ILAR Journal · doi:10.1093/ilar/ilv021 · Cited by 140
Lee, W., & Brey, P. T. (2013) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122333 · Cited by 139
Zheng, T., Yang, X., Li, W., Wang, Q., Chen, L., Wu, D., Bian, F., Xing, S., & Jin, S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8597897 · Cited by 135
The Microbiota-Inflammasome Hypothesis of Major Depression
Inserra, A., Rogers, G. B., Licinio, J., & Wong, M. (2018) · BioEssays · doi:10.1002/bies.201800027 · Cited by 134
Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
Boursier, J., & Diehl, A. M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004559 · Cited by 140
Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis
Schneditz, G., Rentner, J., Roier, S., Pletz, J., Herzog, K. A. T., Bücker, R., Troeger, H., Schild, S., Weber, H., Breinbauer, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403274111 · Cited by 137
Hernández‐Rodas, M. C., Valenzuela, R., Echeverría, F., Rincón‐Cervera, M. Á., Espinosa, A., Illesca, P., Muñoz, P., Corbari, A., Romero, N., Gonzalez‐Mañán, D., et al. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700479 · Cited by 134
Caussy, C., Hsu, C. L., Singh, S., Bassirian, S., Kolar, J., Faulkner, C., Sinha, N., Bettencourt, R., Gara, N., Valasek, M. A., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15035 · Cited by 134
The NLRP6 inflammasome in health and disease
Ghimire, L., Paudel, S., Jin, L., & Jeyaseelan, S. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0256-z · Cited by 136
Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
The gut microbiota and the liver. Pathophysiological and clinical implications
Quigley, E. M. M., Stanton, C., & Murphy, E. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.023 · Cited by 133
The microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 136
Role of Gut Microbiota in Hepatocarcinogenesis
Gupta, H., Youn, G. S., Shin, M. J., & Suk, K. T. (2019) · Microorganisms · doi:10.3390/microorganisms7050121 · Cited by 134
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 138
Dysbiosis of gut microbiota in patients with esophageal cancer
Deng, Y., Tang, D., Hou, P., Shen, W., Li, H., Wang, T., & Liu, R. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104709 · Cited by 133
Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Miele, L., Marrone, G., Lauritano, C., Cefalo, C., Gasbarrini, A., Day, C., & Grieco, A. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811319290011 · Cited by 132
Qu, L., Yu, B., Li, Z., Jiang, W., Jiang, J., & Kong, W. (2015) · Phytotherapy Research · doi:10.1002/ptr.5541 · Cited by 131
Zhang, X., Ji, X., Wang, Q., & Li, J. Z. (2017) · Protein & Cell · doi:10.1007/s13238-017-0436-0 · Cited by 133
Role of interleukins in obesity: implications for metabolic disease
Febbraio, M. A. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.02.004 · Cited by 134
Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes
Chen, X., & Devaraj, S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1104-3 · Cited by 132
Zhang, H., Yan, A., Liu, X., Ma, Y., Zhao, F., Wang, M., Loor, J. J., & Wang, H. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.124489 · Cited by 132
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
